SIA
CANF

Schechter Investment Advisors’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History

Schechter Investment Advisors’s Portfolio CANF Stock Details CANF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,004
Closed -$44.2K – 669
2023
Q4 		$44.2K Buy
+1,004
New +$43.2K ﹤0.01% 592

Other funds holding CANF

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Schechter Investment Advisors's CANF Position: Q1 2024 in Review

Schechter Investment Advisors sold out of Can-Fite BioPharma American Depositary Shares (CANF) in Q1 2024, closing a stake of 1,004 shares — an estimated $44.2K sold.

Schechter Investment Advisors first reported a position in CANF in Q4 2023 and held it in 1 quarter. The position peaked at $44.2K in Q4 2023. 8 funds tracked by Wall St. Rank hold CANF as of Q1 2024.

  • Schechter Investment Advisors reported no remaining Can-Fite BioPharma American Depositary Shares position as of Q1 2024 after selling out during the quarter.
  • Schechter Investment Advisors sold 1,004 Can-Fite BioPharma American Depositary Shares shares in Q1 2024, an estimated $44.2K.
  • Schechter Investment Advisors first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2023 and held it in 1 quarter.
  • Schechter Investment Advisors's Can-Fite BioPharma American Depositary Shares position peaked at $44.2K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2024.

Based on Schechter Investment Advisors's 13F filing for Q1 2024, filed 6 May 2024.